Search Bar & Filters
Found 60 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.
Actively Recruiting
Researchers are evaluating the combination of camizestrant and ribociclib in patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer who have not previously received systemic treatment for their advanced disease. This Phase IIIb, global, multicenter, single-arm study aims to assess the effectiveness, safety, and tolerability of this treatment approach. Participants will receive daily oral doses of camizestrant at 75 mg and ribociclib at 600 mg. All enrolled patients will take these medications until they decide to stop treatment or for any other reason that leads to discontinuation. The study does not involve comparison groups but monitors treatment outcomes in all participants receiving the combination. During the study, participants will undergo evaluations to monitor how long they remain on treatment before starting another therapy or experiencing progression. Researchers will assess treatment safety, including any significant side effects occurring within the first six months. Participants will have regular visits to assess their health status and treatment response. The total study duration extends up to two years following the first dose of treatment.
Actively Recruiting
Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Barrett Esophagus is a condition where the esophageal lining changes, increasing the risk of developing precancerous tissue and adenocarcinoma. This study compares two treatment methods for Barrett Esophagus complicated by dysplasia the new EndoRotor system versus the established Radiofrequency ablation. The aim is to evaluate the effectiveness of these treatments in eradicating Barrett Esophagus and associated dysplasia. The study is randomized and controlled, conducted by the University Hospital, Angers. The EndoRotor system mechanically removes the esophageal mucosa in one session through a device that cuts and aspirates tissue, allowing for histological analysis after treatment. Radiofrequency ablation uses thermal energy to destroy the abnormal mucosa, typically requiring multiple sessions with a debridement step using acetylcysteine spray before ablation. Participants are randomly assigned to receive either EndoRotor or Radiofrequency treatment. Both methods aim to fully eradicate Barrett Esophagus tissue but differ in technique and potential costs. Participants will undergo endoscopic evaluations before and after treatment, with biopsies taken to assess the presence of Barrett Esophagus and dysplasia at 3 and 12 months post-treatment. Safety assessments include monitoring discomfort, pain, and adverse events for up to 3 months. The study also evaluates the quality of tissue samples for pathological analysis, treatment cost-effectiveness, and the number of additional treatment sessions needed. Total participation may last up to a year, with multiple follow-up visits to monitor treatment success and safety.
Actively Recruiting
Researchers are evaluating the efficacy and safety of combining ficlatuzumab with cetuximab compared to cetuximab alone in people with recurrent or metastatic RM HPV-negative head and neck squamous cell carcinoma HNSCC. This Phase 3, randomized, double-blind, placebo-controlled study focuses on participants who have not responded to prior anti-PD-1PD-L1 immune checkpoint inhibitors and platinum-based chemotherapy. The goal is to see if adding ficlatuzumab improves survival outcomes in this patient group. Participants are assigned to one of three groups two groups receive different doses of intravenous ficlatuzumab plus cetuximab on days 1 and 15 of each 28-day cycle, while the third group receives a placebo plus cetuximab on the same schedule. The study will enroll about 410 participants and compare progression-free survival and overall survival among these groups. Treatment cycles continue until disease progression or other study endpoints. During the study, participants will undergo regular imaging scans CT or MRI to assess tumor response every 8 weeks during the first year, then every 12 weeks in years 2 and 3, and every 6 months thereafter. Researchers will monitor safety, quality of life, and immune responses, including antidrug antibodies. The study period spans approximately 44 months with ongoing evaluations from randomization until death or last response assessment.
Actively Recruiting
Researchers are evaluating the investigational drug danicamtiv in people with symptomatic genetic and familial dilated cardiomyopathy DCM. This condition causes the heart muscle to weaken and enlarge, reducing its ability to pump blood effectively. There are currently no approved treatments specifically for genetic or familial DCM, so this study aims to assess the safety and effectiveness of danicamtiv compared to a placebo. The study is conducted by Kardigan, Inc. and focuses on improving heart function and exercise capacity over time. Participants will receive either danicamtiv or a placebo twice daily for about 26 weeks. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the study, participants will visit the clinic approximately 12 times for evaluations, tests, and follow-up. These visits will include echocardiograms to assess heart function and exercise tests to measure physical capacity. During the trial, participants will undergo various assessments such as cardiac imaging, exercise capacity tests, and questionnaires about heart-related symptoms. Researchers will monitor changes in heart function measures like left atrial function index and peak oxygen uptake over 26 weeks. Safety and tolerability of the drug will also be closely observed. The total participation duration is about six months, with regular clinic visits to track progress and collect data.
Actively Recruiting
Researchers are evaluating danicamtiv, an investigational medication, to understand its long-term safety and effectiveness in adults with symptomatic genetic or familial dilated cardiomyopathy DCM. This condition currently has no approved medicines specifically targeting its genetic or familial form. The study aims to explore how well danicamtiv works, its safety, and how well patients can tolerate it over extended use. Participants in this study will take danicamtiv twice daily for up to 5 years. The study involves a single group of participants all receiving the same investigational drug. Regular clinic visits, about 16 in total, will be scheduled for clinical evaluations and diagnostic tests to monitor treatment effects and safety throughout the study period. During the study, participants will undergo assessments including physical examinations, vital sign checks, electrocardiograms ECGs, and clinical laboratory tests. Researchers will also monitor changes in cardiac structure and function using transthoracic echocardiograms and evaluate quality of life through questionnaires such as the Kansas City Cardiomyopathy Questionnaire and EuroQol surveys. Safety will be closely tracked by recording adverse events and disease-related occurrences over the entire 61 months of follow-up.
Actively Recruiting
Crohns disease is a long-term condition causing inflammation that can affect any part of the gut. This research aims to evaluate the safety and effectiveness of TAK-279 compared to a placebo in adults with moderately to severely active Crohns disease. The main goal is to find out if three different doses of TAK-279 can reduce bowel inflammation and ulcers after 12 weeks of treatment using endoscopy to assess the bowel. Participants will be randomly assigned to receive one of three doses of TAK-279 or a placebo capsule, taken orally. The treatment period lasts for 52 weeks, or 1 year. The study includes an initial induction phase with treatment assignment and a 4-week safety follow-up phase after completing treatment. The trial is conducted at multiple centers worldwide and involves about 268 participants. Participants will visit the study clinic 15 times during the study. During these visits, researchers will conduct endoscopies and use scores like the Simple Endoscopic Score for Crohns Disease SES-CD and the Crohns Disease Activity Index CDAI to measure inflammation and disease activity. Quality of life and fatigue will also be assessed using questionnaires. Safety and tolerability will be monitored throughout the study and during the follow-up period, with total participation lasting about 60 weeks.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.
1-10 of 60
1